IL-23 receptor antagonist icotrokinra hit co-primary phase III endpoints in moderate to severe plaque psoriasis, positioning the oral peptide at the forefront of a multibillion-dollar franchise for ...
Protagonist (PTGX) is a high-conviction buy: late-stage icotrokinra & rusfertide near 2026 milestones, strong cash runway. Read more here.
Johnson & Johnson (NYSE:JNJ) is reportedly in discussions to acquire Protagonist Therapeutics (NASDAQ:PTGX). Citing people close to the talks, the Wall Street Journal reported that the deal is not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results